The National Ataxia Foundation (NAF), the Friedreich’s
Ataxia Research Alliance (FARA), and Ataxia UK are pleased to announce the date
for the inaugural International Congress for Ataxia Research (ICAR) to be held at the
Caribe Royale resort in Orlando, Florida, USA on March 15th – 18th, 2022.
The National Ataxia Foundation (NAF) announced today the launch of the NAF Drug Development Collaborative. This pre-competitive pharmaceutical industry consortium has a principal goal of accelerating the development of treatments for Ataxia. The group will address the many shared opportunities and challenges in therapy development for this complex neurological disease.
The National Ataxia Foundation (NAF) Board of Directors and staff announced their new Executive Director, Andrew Rosen, following a nationwide search conducted by a committee of the Board of Directors. He will lead NAF’s efforts in improving the lives of persons affected by Ataxia through support, education, and research.
Non-profit based in Minneapolis will accept resumes from qualified candidates until the position is filled, with submissions to be considered in the first screening due by December 21, 2018. Download Press Release
New preclinical research by Dr. Laura Ranum, a member of NAF’s Medical Research Advisory Board, shows a commonly used Type 2 diabetes drug can improve symptoms in a specific genetic form of ALS and frontotemporal dementia in mice. Read more »
Ataxia is a neurological disease that causes balance and motor coordination problems and other symptoms, according to the NAF. There is no cure for Ataxia but the Walk n’ Roll raises money to help research a cure and support those living with the disease. Read more »
Using biochemical and structural studies, they found that in AOA1, aprataxin mutations affect protein stability, how repair proteins bind to DNA, and the rate of the chemical reaction, which is known as catalysis. The team also uncovered a dominant mutation that affects the enzymatic reaction that normally reverses DNA damage. Read more »